Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
KY/TN Water Profession...KY/TN Water Professionals
Not Confirmed
Not Confirmed
27-30 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
KY/TN Water Profession...KY/TN Water Professionals
Industry Trade Show
Not Confirmed
27-30 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
08 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/first-patient-dosed-in-phase-12-clinical-study-of-novel-egfrher3-bispecific-antibody-drug-conjugate-avzo-1418db-1418-302500882.html
05 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250605783144/en/Avenzo-Therapeutics-Initiates-Phase-12-Clinical-Study-of-AVZO-023-a-Potential-Best-in-Class-Novel-CDK4-Selective-Inhibitor
03 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250603522149/en/Avenzo-Therapeutics-Initiates-Phase-12-Clinical-Study-of-AVZO-1418-a-Potential-Best-in-Class-Novel-EGFRHER3-Bispecific-Antibody-Drug-Conjugate
22 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250522705047/en/Avenzo-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AVZO-1418-a-Potential-Best-in-Class-Novel-EGFRHER3-Bispecific-Antibody-Drug-Conjugate
21 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250521148693/en/Avenzo-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AVZO-023-ARTS-023-a-Potential-Best-in-Class-Novel-CDK4-Selective-Inhibitor
07 Jan 2025
// BUSINESSWIRE
ABOUT THIS PAGE